Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 481 AL 495

Longitudinal Multi-Domain Cognitive Assessment of Anti-Amyloid Monoclonal Antibodies Versus Acetylcholinesterase Inhibitors in Early Alzheimer's Disease: A Systematic Review and Meta-Analysis

Lee CY, Hsu TW, Kao YC, Tseng PT, Hsu CW, Lin YH, Liang CS.

Geriatr Gerontol Int. 2026 Apr;26(4):e70492. doi: 10.1111/ggi.70492.

Characteristics of infusion-related reactions to lecanemab in early Alzheimer's disease: A multicenter real-world study in Northwestern China

Liu P, Liu J, Wang J, Du Y, Liu Z, Zhang H, Zhu A, Zhang G, Meng X, Zhao C, Zhang W, Dang L, Zhang W, Qu Q, Qu Y.

J Prev Alzheimers Dis. 2026 May;13(5):100542. doi: 10.1016/j.tjpad.2026.100542. Epub 2026 Mar 19.

Pharmacotherapeutic landscape for the management of agitation associated with Alzheimer's disease

Jain S, Tunc EB, Grossberg GT.

Expert Opin Pharmacother. 2026 Apr;27(6):531-544. doi: 10.1080/14656566.2026.2662949. Epub 2026 Apr 21.

Angiogenic and anti-angiogenic factors are the shared mechanistic pathways between preeclampsia and Alzheimer's disease: Perspective and take-away

Abbas AM, Al-Kuraishy HM, Al-Maiahy TJ, Al-Gareeb AI, Alharbi W, Fawzy MN, Batiha GE.

Vascul Pharmacol. 2026 Mar;162:107583. doi: 10.1016/j.vph.2026.107583. Epub 2026 Feb 1.

Comparative assessment of donepezil memantine and sodium oligomannate on cognitive decline and neuroinflammation in early Alzheimer's disease

Deng X, Zeng Y, Ding D.

Pak J Pharm Sci. 2026 Apr;39(4):944-957. doi: 10.36721/PJPS.2026.39.4.REG.15270.1.

Improvement of age-related neurocognitive disorders by Ginkgo biloba extract: neuroprotection in focus

Eckert A, Georgescu D, Seifritz E, Müller WE.

Int J Psychiatry Clin Pract. 2026 Jun;30(2):115-128. doi: 10.1080/13651501.2026.2617217. Epub 2026 Jan 23.

Dose-Dependent efficacy and safety of Brexpiprazole in agitation associated with dementia in Alzheimer's disease: A systematic review and meta-analysis

Javaid H, Jha A, Cheema U, Noor M, Cheema S, Arfan M, Aqeel M, Habib E, Saddique MN, Qadri M, Shamoon S.

Neurol Sci. 2026 Jan 29;47(2):208. doi: 10.1007/s10072-025-08649-y.

Cumulative cognitive benefits and brain volume change with anti-amyloid therapies for Alzheimer's disease

Lin YH, Hsu TW, Kao YC, Thompson T, Carvalho AF, Stubbs B, Tseng PT, Hsu CW, Yang FC, Tsai CK, Yu CL, Liang CS, Tu YK.

J Neurol Neurosurg Psychiatry. 2026 May 14;97(6):497-504. doi: 10.1136/jnnp-2025-336691.

The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials

O'Mara A, Mody BP, Mammi M, Simjian T, Ghattas K, Kaliki S, Le NPM, Liew A, Migliore M, Mekary RA.

Neurol Sci. 2026 Jan 12;47(1):149. doi: 10.1007/s10072-025-08602-z.

Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease

Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, De Santis C, Gonzalez-Lorenzo M, Vignatelli L, Filippini G, Richard E.

Cochrane Database Syst Rev. 2026 Apr 16;4(4):CD016297. doi: 10.1002/14651858.CD016297.

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial

Atri A, Apostolova LG, Iwata A, Wessels AM, Atkins A, Lu M, Ye W, Ryan S, Doty EG.

Neurol Clin Pract. 2026 Jun;16(3):e200621. doi: 10.1212/CPJ.0000000000200621. Epub 2026 May 13.

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, Johannsen P, Wichmann CA, Abschneider RM, Leon T, Feldman HH.

Lancet. 2026 May 30;407(10544):2167-2179. doi: 10.1016/S0140-6736(26)00459-9. Epub 2026 Mar 19.

Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer's disease

Iwata A, Sakata Y, Koizumi K, Endo A, Kuang W, Sumitomo K, Ishii M.

J Prev Alzheimers Dis. 2026 May;13(5):100541. doi: 10.1016/j.tjpad.2026.100541. Epub 2026 Mar 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias